English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Objective: To analyze the efficacy of capecitabine (referred to as Cap) single-agent maintenance therapy in the advanced breast cancer. Methods: The subjects of the study were 50 patients with advanced breast cancer who were admitted to the hospital between March 2016 and March 2019. They were divided into groups A and B with 25 cases each. The subjects of these two groups were treated with Cap and conventional method, respectively to compare the efficacy. Results: The efficacy of group A was 96.0% compared to that of group B was 76.0%. The complication rate of group A was 12.0% compared to that of group B was 40.0% (P < 0.05). Conclusion: The patients with advanced breast cancer who received Cap maintenance therapy were benefited from better curative effect and controllable complications, which has high promotion value.

The therapeutic effect of capecitabine single drug maintenance therapy in the advanced breast cancer